New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better treatment strategies, report researchers from Institute of Science Tokyo. Through a comprehensive analysis involving clinical data and in vitro and in vivo experiments, they revealed that the SPP1–CD44–Hedgehog signaling pathway is a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target.
This article was originally published on MedicalXpress.com

